On May 18, 2021, Private equity firm Revival Healthcare Capital (Revival) announced the closing of "RVLHC II" with total capital commitments of $500 million. The fund will pursue strategic growth opportunities in which Revival will invest into a high potential target company where a corporate strategic partner will have a structural option or right to acquire the company in the future. This strategy leverages Revival’s capacity as operators and investors to build collaborative partnerships that increase corporate partners’ probability of return on future growth investments and provide accelerated paths for target companies to advance innovative medical device technologies into global markets.

Additionally, Revival has made its first investment commitment from the new fund of $75 million and is actively engaging with global healthcare leaders to identify opportunities where strategic growth investments can deliver significant value.

A Wilson Sonsini Goodrich & Rosati team including Jim Jensen and Matt Lyons advised Revival on its fund and its first major investment from the fund.

For more information, please see Revival's press release.